menu
    • menu
    [{"orgOrder":0,"company":"SK Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SK Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"SK Bioscience \/ AstraZeneca"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Expanded Collaboration","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SK Bioscience \/ SK bioscience","highestDevelopmentStatusID":"12","companyTruncated":"SK Bioscience \/ SK bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ GSK"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Expanded Collaboration","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SK Bioscience \/ SK bioscience","highestDevelopmentStatusID":"12","companyTruncated":"SK Bioscience \/ SK bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SK Bioscience \/ SK bioscience","highestDevelopmentStatusID":"12","companyTruncated":"SK Bioscience \/ SK bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0.14000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Live Attenuated Varicella Virus","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SK Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Doherty Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Quadrivalent Cell Culture-based Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SK Bioscience \/ Doherty Institute","highestDevelopmentStatusID":"2","companyTruncated":"SK Bioscience \/ Doherty Institute"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SK Bioscience \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"SK Bioscience \/ Sanofi"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Matrix-m1","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SK Bioscience \/ SK bioscience","highestDevelopmentStatusID":"12","companyTruncated":"SK Bioscience \/ SK bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Vaxxas","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Typhoid Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"SK Bioscience \/ SK bioscience","highestDevelopmentStatusID":"4","companyTruncated":"SK Bioscience \/ SK bioscience"}]

    Find Clinical Drug Pipeline Developments & Deals by SK Bioscience

    Menu

    SK Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Typhoid Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Vaxxas

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SK Bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine

                            Details : Under the collaboration, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid to develop a novel vaccine-delivery device combination product using Vaxxas’ high-density microarray patch (HD-MAP) platform technology...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 24, 2023

                            Lead Product(s) : Typhoid Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Vaxxas

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVX-CoV2373,Matrix-m1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Novavax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            SK bioscience Announces Equity Investment in Novavax to Strengthen Strategic Partnership

                            Details : Under the partnership, SK bioscience will explore potential future collaborations with Novavax such as utilizing the Novavax's adjuvant, Matrix-M for advancing protein-based vaccines inclding, Nuvaxovid (NVX-CoV2373) to prevent COVID-19.

                            Brand Name : Nuvaxovid

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 08, 2023

                            Lead Product(s) : NVX-CoV2373,Matrix-m1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Novavax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine...

                            Details : GBP410 (21-Valent pneumococcal conjugate vaccine) vaccine that combines specific proteins with the polysaccharide capsule of Streptococcus pneumoniae, which causes pneumococcal diseases such as pneumonia and invasive pneumococcal disease.

                            Brand Name : GBP410

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 29, 2023

                            Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quadrivalent Cell Culture-based Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Doherty Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SK Bioscience and the Peter Doherty Institute for Infection and Immunity Join Forces Against Influenza

                            Details : SK bioscience and the Doherty Institute will work to support and research in influenza biology, vaccines and antivirals. The program includes testing of anti-influenza compounds to identify new antivirals and development of quadrivalent cell culture-base...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 27, 2023

                            Lead Product(s) : Quadrivalent Cell Culture-based Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Doherty Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Live Attenuated Varicella Virus

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia

                            Details : Sky Zoster vaccine consists live attenuated varicella virus which is administered subcutaneously for the prevention of herpes zoster in adults 50 years of age or older.

                            Brand Name : Sky Zoster

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 09, 2023

                            Lead Product(s) : Live Attenuated Varicella Virus

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : CEPI

                            Deal Size : $140.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            SK Bioscience and CEPI Sign Agreement to Develop mRNA Vaccines

                            Details : Under the agreement, SK bioscience will receive R&D expenses from CEPI. Initial funding will be made available to support phase 1/2 clinical trials of two mRNA vaccine platform projects.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 25, 2022

                            Lead Product(s) : mRNA-based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : CEPI

                            Deal Size : $140.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVX-CoV2373,Matrix-M1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Novavax

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17

                            Details : Nuvaxovid (also known as NVX-CoV2373) achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.

                            Brand Name : Nuvaxovid

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 12, 2022

                            Lead Product(s) : NVX-CoV2373,Matrix-M1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Novavax

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Novavax

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Var...

                            Details : Under the agreement, SK bioscience, for the manufacturing and supply of a version of the Novavax COVID-19 vaccine (NVX-CoV2373) containing Omicron variant and for the manufacture of the vaccine in prefilled syringes.

                            Brand Name : Covovax

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 19, 2022

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Novavax

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GBP510

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GSK and SK bioscience's COVID Vaccine Submitted for S.Korea Approval

                            Details : Protein-based SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 ‘GBP510’ with GSK pandemic adjuvant demonstrates superior neutralising titres compared to a control vaccine and clinically favourable safety profile.

                            Brand Name : SKYCovione

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 29, 2022

                            Lead Product(s) : GBP510

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Novavax

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

                            Details : Nuvaxovid (NVX-CoV2373), a first protein-based COVID-19 vaccine inhibit SARS-CoV-2 protein, granted approval in South Korea in collaboration with SK bioscience, where the biologics license application was submitted to the MFDS in November.

                            Brand Name : Nuvaxovid

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 12, 2022

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Novavax

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth